Clinical Trial

A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

Study acronym: SoGreat
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
SoGreat is an open-label, single-arm, modular, two-stage, Phase Ib/II study. SoGreat (Part 1) is an open-label, modular, Phase Ib study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-01.
Trial Details
NCT Number NCT07163481
Lead Sponsor Hunan Cancer Hospital
Collaborators: Gilead Sciences
Conditions Stage IV (Metastatic) Breast Cancer
Enrollment 12 participants
Start Date 2025-10
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-16